CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
LY2584702 Reference Formulation +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01372085
NCT01372085Phase 1Completed
CompareCT.gov

A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jun 13, 2011·Updated Jan 22, 2019

In Brief

A Phase 1 clinical trial evaluating LY2584702 Reference Formulation, LY2584702 Test Formulation, and 1 other intervention for Healthy Participants. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This is a single-centre, placebo-controlled, two-part study in healthy participants. Part A will be a single dose, single period, placebo-controlled pilot study to explore the safety, tolerability, absorption and pharmacodynamic \[effect of drug on a biological marker-phospho-S6 (pS6) levels in skin biopsies\] of a single dose of 25 milligrams (mg) LY2584702 Reference formulation (RF). Part B is a single dose, placebo-controlled, 4-period crossover study to primarily evaluate the absorption of the Test Formulation (TF) in comparison with the (RF) of LY2584702.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 13, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.1 years ago

Interventions

LY2584702 Reference Formulationdrug

Administered orally

LY2584702 Test Formulationdrug

Administered orally

Placebodrug

Administered orally